Iasocholine

Fluorocholine (18F) Chloride, the active ingredient in Iasocholine, is a radiopharmaceutical presented as a sterile solution for injection for intravenous use. It is employed to visualize tissues with increased phospholipid synthesis, primarily in patients undergoing PET imaging for prostate cancer and other malignancies that exhibit high choline metabolism.

GNH USA supplies Iasocholine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, diagnostic imaging facilities and research institutions worldwide, with adherence to EU quality standards. The product complies with European Union regulatory requirements for radiopharmaceuticals.

Iasocholine is used in PET imaging to assess cancers that demonstrate elevated choline metabolism.

- Prostate cancer: enables PET imaging to detect, localize and stage disease, improving treatment planning. - High‑grade glioma: facilitates visualization of proliferating tumor tissue for diagnostic and therapeutic monitoring. - Other malignant lesions with high choline uptake: assists in locating and characterizing tumors such as head‑and‑neck or lung cancers where choline metabolism is increased.

Adverse reactions to Iasocholine are generally related to the injection procedure and the radiopharmaceutical nature of the product.

Common Side Effects: - Injection site discomfort: mild pain or irritation at the site of administration. - Nausea: transient feeling of sickness after injection. - Flushing: brief warmth or redness of the skin. - Headache: mild to moderate headache occurring shortly after dosing. - Dizziness: temporary light‑headedness. - Fatigue: short‑term tiredness post‑administration.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure that may cause fainting. - Cardiac arrhythmia: irregular heart rhythm potentially life‑threatening. - Radiation‑induced skin injury: localized tissue damage at high exposure sites.

Specific safety considerations should be observed when using Iasocholine.

- Pregnancy: unknown risk; avoid unless diagnostic benefit outweighs potential harm. - Breastfeeding: unknown; consider discontinuing nursing during and after administration. - Renal impairment: assess renal function; altered clearance may affect tracer distribution. - Hepatic impairment: use with caution; monitor for possible accumulation. - Known hypersensitivity: contraindicated in patients with allergy to fluorocholine or any formulation component. - Store at 2–8 °C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may influence tracer uptake or patient safety.

Major Interactions (Avoid): - Concurrent administration of other PET tracers: may cause competitive uptake and interfere with image interpretation. - High‑dose corticosteroids: can suppress choline kinase activity, reducing tracer accumulation. - Certain chemotherapeutic agents: may alter membrane synthesis, diminishing tracer uptake.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect cardiovascular response to injection. - Diuretics: can modify renal excretion of the tracer. - Iodinated contrast agents: may affect PET quantification if performed shortly before or after tracer injection.